Vir Biotechnology, Inc. (VIR) Fair Value 2026

VIR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-27, Vir Biotechnology, Inc. (VIR) trades at $11.31. QOC: 6.5/10. Value Trap Risk: 19/100 (SAFE). 0/13 models active.

Key Facts

Ticker
VIR
Price
$11.31
Quality Score
6.5/10
Value Trap Risk
19/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give VIR?

0 Intrinsic Value Models vs. Current Price ($11.31)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Vir Biotechnology, Inc. (VIR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Vir Biotechnology, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About VIR?

0 of 13 models are currently active for VIR. See which stocks rank higher →

How Does VIR Rank in Biotechnology?

Among 620 Biotechnology stocks, VIR ranks #83 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Vir Biotechnology, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is VIR a Value Trap?

CirclFi's Value Trap algorithm assigns VIR a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Vir Biotechnology, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Vir Biotechnology, Inc.'s fundamental quality profile registers 6.5/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every VIR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Vir Biotechnology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ZEOXZeo ScientifiX, Inc.QOC 6.6ZVRAZevra Therapeutics, Inc.QOC 6.5TVTXTravere Therapeutics, Inc.QOC 6.6ASNDAscendis Pharma A/SQOC 6.5AXSMAxsome Therapeutics, Inc.QOC 6.6ARDXArdelyx, Inc.QOC 6.5MANEVeradermics, IncorporatedQOC 5.4MOLNMolecular Partners AGQOC 4.7OMEROmeros CorporationQOC 3.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ZEOX · ZVRA · TVTX · ASND · AXSM · ARDX · MANE · MOLN · OMER · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to VIR?

7 companies across all industries closest to VIR’s Quality of Company score of 6.5/10.

SDRLSeadrill LimitedQOC 6.5TELATELA Bio, Inc.QOC 6.5SYSo-Young International Inc.QOC 6.5TGBTrekor Metals LimitedQOC 6.5PESIPerma-Fix Environmental Services, Inc.QOC 6.6ROCRank One Computing CorporationQOC 6.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SDRL · TELA · SY · TGB · PESI · ROC · NVDA

Where Does VIR Sit in CirclFi's Biotechnology Rankings?

VIR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Vir Biotechnology, Inc.’s Valuation?

What is Vir Biotechnology, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Vir Biotechnology, Inc. (VIR). The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is VIR overvalued or undervalued right now?

At $11.31, 0 of 0 active models suggest VIR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Vir Biotechnology, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.5 mean for VIR?

Vir Biotechnology, Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on VIR?

CirclFi analyzes VIR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is VIR a value trap in 2026?

Vir Biotechnology, Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Vir Biotechnology, Inc. (VIR) a Quality of Company score of 6.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/VIR/ · Methodology
Primary sources for this VIR valuation
  • Financial statements: Vir Biotechnology, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001706431) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for VIR as of ; valuations recomputed .